blue cross cover glp 1 IBX members face GLP-1 drug costs after insurance change Blue Cross Blue Shield of
Description
No shots
L., & Purnell, J
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
By route of administration, injectable pens held 91.68% revenue in 2025, whereas oral tablets are expected to post a 10.35% CAGR over 2026-2031
Shortage Status Changes The FDA declared the semaglutide shortage resolved in February 2025
